Wuhan Hiteck Biological Pharma Co.,Ltd (SHE:300683)

China flag China · Delayed Price · Currency is CNY
35.34
+0.09 (0.26%)
Apr 30, 2026, 3:12 PM CST
60.78%
Market Cap 4.61B
Revenue (ttm) 543.82M
Net Income (ttm) -240.38M
Shares Out 130.89M
EPS (ttm) -1.83
PE Ratio n/a
Forward PE n/a
Dividend 0.13 (0.37%)
Ex-Dividend Date n/a
Volume 5,103,200
Average Volume 13,627,994
Open 32.26
Previous Close 35.25
Day's Range 32.26 - 35.50
52-Week Range 21.80 - 61.76
Beta 0.01
RSI 48.31
Earnings Date Apr 24, 2026

About SHE:300683

Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Epramine for injection; mouse nerve growth factor for injection; Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; adenosine cyclophosphate for injection that is used for angina pec... [Read more]

Sector Healthcare
Founded 1992
Employees 1,309
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300683
Full Company Profile

Financial Performance

In 2025, SHE:300683's revenue was 541.45 million, a decrease of -16.57% compared to the previous year's 648.97 million. Losses were -231.27 million, 233.5% more than in 2024.

Financial Statements

News

There is no news available yet.